

INTERIM REPORT Q1

September 2023 – November 2023

Stem and stromal cells are expected to revolutionize the treatment of severe and incurable diseases. NextCell develops groundbreaking cell therapies for the treatment of primarily autoimmune and inflammatory diseases. We have come the furthest with ProTrans for the treatment of type 1 diabetes. NextCell also operates Cellaviva, Scandinavia's largest stem cell bank.



Cellaviva™ NextCell's stem cell bank, which offers family saving of stem cells for possible future medical needs - the largest in Scandinavia.



ProTrans™ NextCell's patented proprietary cell product for the treatment of autoimmune and other inflammatory diseases. Significant effect shown in diabetes.

Content

| | |
|--|----|
| 01. Interim Report Q1 | 3 |
| 02. CEO comments | 4 |
| 03. Development in numbers during the period | 5 |
| 04. Income Statement..... | 7 |
| 05. Balance sheet..... | 8 |
| 06. Cash flow statement | 10 |
| 07. Statement of changes in equity..... | 11 |

Company information

Company name: NextCell Pharma AB (Publ.)

Organization number: 556965-8361

Legal corporate form: Public limited company

Place: Huddinge

Trading place: Nasdaq First North Growth Market

Address: Hälsövägen 7, 141 57 Huddinge

Telephone: +46 8 735 55 95

Web page: www.nextcellpharma.com | www.cellaviva.se

Certified Adviser: FNCA Sweden AB

Interim Report Q1 01.

NextCell – part of the cell therapy revolution

"NextCell", "NXTCL", or "Company" refers to NextCell Pharma AB, organization number 556965-8361. The amount in brackets refers to the corresponding period during the previous year. Note that the Company's fiscal year is September 1 - August 31. This English version of the Interim Report is a translation of the Swedish version. The Swedish version is the official version.

First quarter (2023-09-01 until 2023-11-30)

- Operating income amounted to 4,695 (3,012) TSEK, of which Cellaviva amounted to 4,218 (2,137) TSEK.
- Operating result amounted to -9,796 (-8,918) TSEK.
- Earnings per share* amounted to -0.28 (-0.26) SEK.
- Cash and Bank amounted to 40,428 (88,258) TSEK.
- Solidity** amounted to 82.2 (92.7) percent.

**Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2023/2024: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of November 30, 2023: 34,379,523 (34,379,523) shares.*

***Solidity: Equity to total balance sheet.*

Significant events in the first quarter

- NextCell Pharma AB ("NextCell" or "the company") announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.

Significant events after the reporting period

- At the end of January, NextCell published an update on the ongoing clinical trials. The largest ongoing study – ProTrans Young, which includes 66 patients – is progressing well.



CEO comments

02.

The first quarter of our split financial year has been taken into account and Cellaviva's revenues landed at over 4.2 million SEK. This is yet another sales record and Cellviva is increasingly contributing to the financing of the business. In addition, our studies are progressing well. The older age group in the "diabetes child study" is fully recruited and the first patient with severe pneumonia caused by the virus has undergone treatment in the ProTrans19+SE study. Moreover, it is time to summarise our important follow-up studies.

During the autumn, Professor Per-Ola Carlsson and his team in Uppsala, together with Professor Helena Eldring Larsson at Skåne University Hospital, have been progressing with the paediatric study. After a short Christmas break, the last patients were recruited in the older age group, 12-21 years old. The patients are followed for a few weeks before treatment is given. Three months later, the data are analysed by a safety committee. Provided that the treatment is considered safe, recruitment of the younger age group can then start, which will probably take place in August.

It has now been 6 years since the first diabetes patient was treated with ProTrans. After the patient completed the ProTrans-1 study according to protocol after 12 months, he was asked to participate in an additional study to be treated with another dose of ProTrans, and then followed up for additional 5 years. I would like to take this opportunity to thank him and all the other patients who have participated in our studies. Thanks to you, this year we will be able to summarize both ProTrans-Obs and ProTrans-Repeat with 5 and 6 years of data, respectively.

ProTrans slows down the progression of the disease

So far, our analysis of the 3-year data have shown that ProTrans can significantly delay the progression of type 1 diabetes. This is a result that, to my knowledge, no other immunomodulatory treatment has achieved. In addition, the treatment is simple, safe, and cost-effective. The pricing level of ProTrans depends on the size of the effect and how long it lasts. If we compare with the drug Tzield, which has a price of just under 200 kUSD for one treatment

(only the drug, other costs for premedication and hospital fees cost an additional 40 kUSD). The effect of Tzield lasts for two years.

Soon we will have 5-year data for treatment with ProTrans, which will be a great asset when we calculate the value of ProTrans. If we can show that the effect of ProTrans lasts for several years, our drug should be priced significantly higher than USD 100,000 which we have previously stated as an indicative price.

Cellaviva has significantly increased sales. This is mainly due to increased sales of stem cell banking; in addition, we have sales of tissue products and genetic tests. Last autumn, we announced that Cellaviva had entered into an agreement for the distribution of tissue products to clinics. A couple of months later, the first deliveries were made.

Cellaviva acts as an intermediary between manufacturers and hospitals and clinics. This new activity is regulated by the Tissue Directives, with the Swedish Health Authorities (IVO) as the supervisory authority, in the same way as with the stem cell bank. This means that Cellaviva has a unique position and can offer advanced business-2-business services without having to invest in permit applications, quality systems and infrastructure; they are already in place. I see good opportunities to expand this business as we have already received new customer inquiries without even marketing the service.

Thank you for your continued support.

Mathias Svahn, Ph.D.
VD NextCell Pharma AB



Soon we will have 5-year data for treatment with ProTrans, which will be a great asset when we calculate the value of ProTrans.

Development in numbers during the period

03.

CFO Patrik Fagerholm comments on financial development.

Turnover

Operating income for the first quarter of 2023/2024 amounts to SEK 4.7 (3.0) million, of which SEK 4.2 (2.1) million refers to revenue from Cellaviva's operations, which means an increase of almost 100 percent between the periods. Other income for the first quarter of 2023/2024 amounts to SEK 0.5 (0.9) million, which consists of the new operations with Linio SEK 0.3 million and research grants SEK 0.2 million. Revenues related to Cellaviva continue to show steady growth.

Financial development

The result for the first quarter 2023/2024 amounts to SEK -9.8 (-8.9) million and the total cost base for the period amounts to SEK -14.9 (-12.1) million which means an increase of SEK 2.8 million (23 percent). The increase is in line with the budget and can mainly be attributed to costs for subconsultants, who worked on the completion of the GMP facility.

Liquidity

NextCell's cash and cash equivalents as of November 30, 2023 amounted to SEK 40.4 (88.2) million. The total cash

flow of the first quarter of 2023/2024 amounted to SEK -9.6 (-8.9) million. Cash flow from operating activities for the first quarter is MSEK -10.0 (-8.4).

Solidity

The company's equity/assets ratio as of November 30, 2023 was 81.3 (92.70) percent.

The stock and the largest shareholders

The company's shares are listed on First North Growth Market and traded under the ticker "NXTCL". As of November 30, 2023, the number of shares amounted to 34,379,523 (34,379,523) and the share capital to SEK 7,047,802 (7,047,802). The average number of shares during the first quarter was 34 379 523 (34 379 523). All shares are of the same class and denominated in Swedish kronor (SEK).

As of December 29, 2023, the number of shareholders was approximately 2,400 (2,100). The ten largest shareholders held shares corresponding to 45.2 percent of the total number.

The list below shows the ten largest shareholders in NextCell as of 29/12/2023

| NAME | NO. OF SHARES | VOTES AND CAPITAL (%) |
|--|-------------------|-----------------------|
| Diamyd Medical AB | 4,283,861 | 12.5 |
| Försäkringsbolaget Avanza Pension | 3,544,213 | 10.3 |
| Anders Essen-Möller | 2,557,955 | 7.4 |
| Ålandsbanken i ägares ställe | 1,245,268 | 3.6 |
| Pabros AB | 847,452 | 2.5 |
| Konstruktions o Försäljningsaktiebolaget KFAB | 746,940 | 2.2 |
| Nordnet Pensionsförsäkring AB | 650,000 | 1.9 |
| Nordea Livförsäkring Sverige AB | 609,803 | 1.8 |
| Robert Joki | 562,353 | 1.6 |
| Mathias Svahn | 507,261 | 1.5 |
| Summa 10 största | 15,555,156 | 45.2 |
| Övriga | 18,824,367 | 54.8 |
| Totalt | 34,379,523 | 100.0 |



Accounting principles for the preparation of the Year-End Report

The Year-End Report has been prepared in accordance with the Annual Accounts Act and BFAR 2012:1 Annual Report and Consolidated Accounts ("K3") and in accordance with BFAR 2007:1 ("Voluntary Interim Reporting"). For further information on accounting policies, we refer to NextCell's Annual Report for 2022/2023.

Auditor's review

The Interim Report has not been reviewed by the Company's auditor.

Certified Adviser

Companies affiliated with Nasdaq First North Growth Market require a Certified Adviser. NextCell has appointed FNCA Sweden AB as Certified Adviser.

Financial calendar

The company prepares and publishes a financial report at the end of each quarter. Upcoming reports and events are planned as follows:

| | |
|-----------------------------|------------|
| Q2 report | 25-04-2024 |
| Q3 report | 25-07-2024 |
| Year-End report | 24-10-2024 |
| Annual report | 07-11-2024 |
| Annual Shareholders Meeting | 28-11-2024 |



Publication of the Year-End Report

Huddinge, 25 January 2024
NextCell Pharma AB

Board of Directors and CEO

Anders Essen-Möller
CHAIRMAN OF THE BOARD

Camilla Myhre Sandberg
BOARD MEMBER

Hans-Peter Ekre
BOARD MEMBER

Edvard Smith
BOARD MEMBER

Mathias Svahn
CHIEF EXECUTIVE OFFICER

Income Statement 04.

| (SEK) | 2023-09-01 | 2022-09-01 | 2022-09-01 |
|---------------------------------------|--------------------|--------------------|--------------------|
| | 2023-11-30 | 2022-11-30 | 2023-08-31 |
| | 3months | 3months | 12months |
| Operating Income | | | |
| Net Income | 4,246,122 | 2,136,967 | 10,113,474 |
| Other Operating Income | 448,557 | 875,401 | 3,841,880 |
| Total Operating Income | 4,694,679 | 3,012,368 | 13,955,354 |
| Operating Expense | | | |
| Material and goods | -2,666,749 | -2,249,912 | -10,998,308 |
| Other external costs | -7,474,144 | -6,371,584 | -28,662,077 |
| Personnel costs | -4,609,029 | -3,347,856 | -14,809,594 |
| Depreciation | -111,970 | -111,968 | -447,875 |
| Other operating costs | 4,107 | -8,585 | -39,639 |
| Total operating expense | -14,857,786 | -12,089,905 | -54,957,493 |
| Operating result | -10,163,106 | -9,077,537 | -41,002,139 |
| Financial income and expense | | | |
| Interest received | 367,369 | 162,005 | 1,193,320 |
| Interest expense and similar expenses | 0 | -2,685 | -2,812 |
| Total financial items | 367,369 | 159,320 | 1,190,508 |
| Result before tax | -9,795,737 | -8,918,217 | -39,811,631 |
| Taxes | | | |
| Tax expense for the period | 0 | 0 | 0 |
| Net result for the period | -9,795,737 | -8,918,217 | -39,811,631 |



Balance sheet

05.

| (SEK) | 2023-11-30 | 2022-11-30 | 2023-08-31 |
|--|-------------------|--------------------|-------------------|
| ASSETS | | | |
| Non current assets | | | |
| <i>Tangible non-current assets</i> | | | |
| Property, plant and equipment | 811,925 | 1,145,573 | 895,337 |
| Inventories, tools and equipment | 1,037,912 | 1,152,141 | 1,066,470 |
| Fixed assets in progress | 11,633,492 | 8,134,466 | 11,590,077 |
| | 13,483,329 | 10,432,180 | 13,551,884 |
| <i>Financial assets</i> | | | |
| Shares and interest in other companies | 6,871,525 | 6,871,525 | 6,871,525 |
| Other long-term receivables | 1,131,342 | 1,128,193 | 1,131,342 |
| | 8,002,867 | 7,999,718 | 8,002,867 |
| Total non-current assets | 21,486,195 | 18,431,897 | 21,554,750 |
| Current assets | | | |
| <i>Stock and inventory</i> | | | |
| Raw material | 790,666 | 766,969 | 790,666 |
| <i>Current receivables</i> | | | |
| Trade receivables | 2,311,367 | 1,282,441 | 2,349,174 |
| Other receivables | 1,565,203 | 1,043,674 | 1,235,498 |
| Prepaid expenses and accrued income | 14,636,299 | 6,154,121 | 12,872,070 |
| | 18,512,869 | 8,480,237 | 16,456,742 |
| Liquid assets | 40,428,250 | 88,258,952 | 50,025,162 |
| Total current assets | 59,731,785 | 97,506,158 | 67,272,571 |
| TOTAL ASSETS | 81,217,981 | 115,938,055 | 88,827,321 |

Balance sheet cnd.

| (SEK) | 2023-11-30 | 2022-11-30 | 2022-08-31 |
|-------------------------------------|-------------------|--------------------|-------------------|
| EQUITY AND LIABILITIES | | | |
| Equity | | | |
| <i>Restricted equity</i> | | | |
| Share capital | 7,047,802 | 7,047,802 | 7,047,802 |
| <i>Non-restricted equity</i> | | | |
| Profit or loss brought forward | -127,750,206 | -87,938,575 | -87,938,575 |
| Shareholders surplus | 196,429,502 | 196,429,502 | 196,429,502 |
| Result for the period | -9,795,737 | -8,918,217 | -39,811,631 |
| | 58,833,559 | 99,572,710 | 68,679,296 |
| Total equity | 65,931,361 | 106,620,512 | 75,727,098 |
| Liabilities | | | |
| <i>Long-term liabilities</i> | | | |
| Other long-term liabilities | 3,426,037 | 2,358,827 | 3,020,266 |
| <i>Current liabilities</i> | | | |
| Trade payables | 2,250,046 | 2,083,641 | 891,620 |
| Other liabilities | 1,769,623 | 737,005 | 1,345,374 |
| Prepaid income and accrued expenses | 7,840,914 | 4,138,069 | 7,842,964 |
| | 11,860,583 | 6,958,716 | 10,079,958 |
| Total liabilities | 15,286,620 | 9,317,543 | 13,100,223 |
| TOTAL EQUITY AND LIABILITIES | 81,217,981 | 115,938,055 | 88,827,321 |



Cash flow statement

06.

| (SEK) | 2023-09-01 | 2022-09-01 | 2022-09-01 |
|--|-------------------|-------------------|--------------------|
| | 2023-11-30 | 2022-11-30 | 2023-08-31 |
| | 3 months | 3 months | 12 months |
| Operating activities | | | |
| Operating profit/loss | -10,163,106 | -9,006,195 | -41,002,139 |
| Non-cash flow items | | | |
| Depreciation | 111,970 | 111,968 | 447,875 |
| Interest received | 367,369 | 162,005 | 1,193,320 |
| Interest paid | 0 | -2,685 | -2,812 |
| Cash flow from operating activities before changes in working capital | -9,683,767 | -8,734,907 | -39,363,756 |
| Changes in working capital | | | |
| Increase/decrease in receivables | -2,056,127 | 318,899 | -7,586,265 |
| Increase/decrease in payables | 422,199 | -132,454 | 4,180,810 |
| Increase/decrease in stock and inventories | 0 | 0 | -23,697 |
| Increase/decrease in short term payables | 1,358,426 | 159,235 | -1,032,787 |
| Total of working capital | -275,502 | 345,681 | -4,461,939 |
| Net cash flow from operating activities | -9,959,269 | -8,389,226 | -43,825,695 |
| Investing activities | | | |
| Investments in tangible fixed assets | -43,415 | -643,259 | -4,098,869 |
| Investments in financial fixed assets | - | - | -3,149 |
| Net cash flow from investment activities | -43,415 | -643,259 | -4,102,018 |
| Financing activities | | | |
| Long term liabilities | 405,771 | 174,226 | 835,664 |
| Net cash flow from financing activities | 405,771 | 174,226 | 835,664 |
| Cash flow for the period | | | |
| Cash and cash equivalents at beginning of the period | 50,025,162 | 97,117,211 | 97,117,211 |
| Change in cash and cash equivalents | -9,596,912 | -8,858,259 | -47,092,049 |
| CASH AND CASH EQUIVALENTS AT END OF THE PERIOD | 40,428,250 | 88,258,952 | 50,025,162 |

Statement of changes in equity 07.

| | SHARE CAPITAL | BALANCED RESULT | SHARE PREMIUMS | NET RESULT OF THE PERIOD | TOTAL EQUITY |
|-----------------------------------|---------------|-----------------|----------------|--------------------------|--------------|
| Opening balance 01-09-2022 | 7,047,802 | -53,384,260 | 196,429,502 | -34,554,315 | 115,538,729 |
| Disposition from AGM | | -34,554,315 | | 34,554,315 | 0 |
| Result | | | | -39,811,631 | -39,811,631 |
| Closing balance 31-08-2023 | 7,047,802 | -87,938,575 | 196,429,502 | -39,811,631 | 75,727,098 |

| | SHARE CAPITAL | BALANCED RESULT | SHARE PREMIUMS | NET RESULT OF THE PERIOD | TOTAL EQUITY |
|-----------------------------------|---------------|-----------------|----------------|--------------------------|--------------|
| Opening balance 01-09-2023 | 7,047,802 | -87,938,575 | 196,429,502 | -39,811,631 | 75,727,098 |
| Disposition from AGM | | -39,811,631 | | 39,811,631 | 0 |
| Result | | | | -9,795,737 | -9,795,737 |
| Closing balance 30-11-2023 | 7,047,802 | -127,750,206 | 196,429,502 | 9,795,737 | 65,931,361 |





nextcell
pharma